Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491699 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
A Phase 1 study, sponsored by Symphony Evolution.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00491699: Clinical Trial Phase 1 study, sponsored by Symphony Evolution.
NCT00491699 is a Phase 1 study that was terminated before completion, run by Symphony Evolution. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00491699, a Phase 1 study, was terminated before completion, sponsored by Symphony Evolution.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Interventions
- DRUG XL999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Why NCT00491699 stopped before completion
NCT00491699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which XL999 is the first listed.
NCT00491699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00491699 about?
NCT00491699 is a clinical study titled "Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer". The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blo...
What is the current status of trial NCT00491699?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-08. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00491699?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00491699?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00491699's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia